Project Updates
Gritgen Therapeutics
Credit:Gorodenkoff/Shutterstock.com
Location: Suzhou, China
Project type: GMP Gene Therapy Facility
Size: 8,600m2
Opening: October 2023
Gritgen Therapeutics, a biotechnology company based in China, opened a good manufacturing practice (GMP) facility in Suzhou Industrial Park in Suzhou, China, for commercial production of plasmid and adeno-associated virus (AAV)-based products in October 2023.
MaaT Pharma
Credit:MaaT Pharma
Location: Saint-Quentin-Fallavier, France
Project type: Microbiome Ecosystem Therapies Manufacturing Facility
Construction Started: July 2022
Completed: September 2023
MaaT Pharma, a biotech company based in France, has built a cGMP microbiome ecosystem therapeutics manufacturing facility near Lyon (Saint-Quentin-Fallavier) in France in collaboration with Skyepharma, a French pharmaceutical contract development and manufacturing organisation (CDMO).
Merck KGaA
Credit:Merck KGaA
Location: Nantong, China
Project type: Reagent Manufacturing Facility
Estimated Investment: €70m
Area: 40,000m2
Germany-based pharmaceutical company Merck will expand its capacity with a new reagent production plant at its existing Nantong site in China. The facility will be utilised for manufacturing of high-purity reagents used in quality control and testing by biopharmaceutical customers.
